Inhibrx Biosciences reported its financial results for the first quarter of 2025, showing a net loss of $43.311 million, an improvement from the $78.710 million net loss in the same period of 2024. This improvement was driven by significant reductions in operating expenses.
Research and development expenses decreased by 42% to $36.877 million in Q1 2025, down from $63.851 million in Q1 2024. General and administrative expenses also fell by 40% to $6.024 million, compared to $9.974 million in the prior year.
As of March 31, 2025, the company held cash and cash equivalents of $216.520 million. Based on current operating plans, Inhibrx believes its existing cash and cash equivalents are sufficient to fund operations for at least 12 months from the May 14, 2025, filing date.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.